Fenglin Lv

Dr. Fenglin Lv


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FYFeng Yang
Feng Yang
JGJiang Gu
Jiang Gu
LYLiuyang Yang
Liuyang Yang
CGChen Gao
Chen Gao
HJHaiming Jing
Haiming Jing
JZJinyong Zhang
Jinyong Zhang
Pseudomonas aeruginosa is a formidable pathogen that is responsible for a diverse spectrum of human infectious diseases, resulting in considerable annual mortality rates. Because of biofilm formation and its ability of rapidly acquires of resistance to many antibiotics, P. aeruginosa related infections are difficult to treat, and therefore, developing an effective vaccine is the most promising method for combating infection. In the present study, we designed a novel trivalent vaccine, PcrV28-294-OprI25-83-Hcp11-162 (POH), and evaluated its protective efficacy in murine pneumonia and burn models. POH existed as a dimer in solution, it induced better protection efficacy in P. aeruginosa lethal pneumonia and murine burn models than single components alone when formulated with Al(OH)3 adjuvant, and it showed broad immune protection against several clinical isolates of P. aeruginosa. Immunization with POH induced strong immune responses and resulted in reduced bacterial loads, decreased pathology, inflammatory cytokine expression and inflammatory cell infiltration. Furthermore, in vitro opsonophagocytic killing assay and passive immunization studies indicated that the protective efficacy mediated by POH vaccination was largely attributed to POH-specific antibodies. Taken together, these data provided evidence that POH is a potentially promising vaccine candidate for combating P. aeruginosa infection in pneumonia and burn infections.

18 February 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LHLeilei He
Leilei He
LGLixia Gao
Lixia Gao
CSChloe Shay
Chloe Shay
LLLiwei Lang
Liwei Lang
FLFenglin Lv
Fenglin Lv
Yong TengYong Teng
Yong Teng
A promising arsenal of histone deacetylase (HDAC)-targeted treatment has emerged in the past decade, as the abnormal targeting or retention of HDACs to DNA regulatory regions often occurs in many cancers. Head and neck squamous cell carcinoma (HNSCC) is one of the most aggressive malignancies worldwide associated with poor overall survival in late-stage patients. HDAC inhibitors have great potential to treat this devastating disease; however, few has been studied regarding the beneficial role of HDAC inhibition in anti-HNSCC therapy and the underlying molecular mechanisms remain elusive. Cell migration and invasion were examined by wound closure and Transwell assays. Protein levels and interactions were assessed by Western blotting and immunoprecipitation. HDAC activity was measured with the fluorometric HDAC Activity Assay. Phospho-receptor tyrosine kinase (RTK) profiling was determined by the Proteome Profiler Human Phospho-RTK Array. ADP-ribosylation factor 1 (Arf1), a small GTPase coordinating vesicle-mediated intracellular trafficking, can be inactivated by HDAC inhibitors through histone acetylation-independent degradation of epidermal growth factor receptor (EGFR) in HNSCC cells. Mechanistically, high levels of Arf1 activity are maintained by binding to phosphorylated EGFR which is localized on HNSCC cell plasma membrane. Decreased EGFR phosphorylation is associated with reduced EGFR protein levels in the presence of TSA, which inactivates Arf1 and eventually inhibits invasion in HNSCC cells. Our insights explore the critical role of EGFR-Arf1 complex in driving HNSCC progression, and demonstrate the selective action of HDAC inhibitors on this specific axis for suppressing HNSCC invasion. This novel finding represents the first example of modulating the EGFR-Arf1 complex in HNSCC by small molecule agents.

1 February 2021 in Life Sciences
Verified
Journal Article
Closed access
DZDan Zeng
Dan Zeng
CCChao Chen
Chao Chen
WZWei Zhou
Wei Zhou
XMXuesu Ma
Xuesu Ma
XPXi Pu
Xi Pu
FLFenglin Lv
Fenglin Lv

23 May 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
FYFeng Yang
Feng Yang
JGJiang Gu
Jiang Gu
JZJintao Zou
Jintao Zou
LLLanghuan Lei
Langhuan Lei
HJHaiming Jing
Haiming Jing
JZJinyong Zhang
Jinyong Zhang
Pseudomonas aeruginosa is a formidable pathogen that causes infections with high mortality rates. Because of its ability to form biofilms and rapidly acquire resistance to many first-line antibiotics, P. aeruginosa-related infections are typically difficult to cure by traditional antibiotic treatment regimes. Thus, new strategies to prevent and treat such infections are urgently required. PA0833 is a newly identified protective antigen of P. aeruginosa that was identified in a screen using a reverse vaccine strategy in our laboratory. In this study, we further confirmed its protective efficacy in murine sepsis and pneumonia models. Immunization with PA0833 induced strong immune responses and resulted in reduced bacterial loads; decreased pathology, inflammatory cytokine expression and inflammatory cell infiltration; and improved survival. Furthermore, PA0833 was identified as an OmpA C-like protein by bioinformatics analysis and biochemical characterization and shown to contribute to bacterial environmental stress resistance and virulence. These results demonstrate that PA0833 is an OmpA C-like protein that induces a protective immune response in mice, indicating that PA0833 is a promising antigen for vaccine development.

27 November 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YCYingli Chen
Yingli Chen
FYFeng Yang
Feng Yang
JYJun Yang
Jun Yang
YHYali Hou
Yali Hou
LHLeilei He
Leilei He
FLFenglin Lv
Fenglin Lv

18 June 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
YWYongzhong Wang
Yongzhong Wang
QLQiang Liao
Qiang Liao
FLFenglin Lv
Fenglin Lv
Xun ZhuXun Zhu
Xun Zhu
Ran YaoRan Yao
Ran Yao
Changjun HouChangjun Hou
Changjun Hou
Solid simultaneous saccharification and fermentation (SSSF) of rice straw for ethanol production using N2 stripping was developed. The effects of N2 flow rate, yeast inoculation amount, and substrate moisture content on SSSF were investigated. The highest total output of ethanol was 4.78 g, and the highest ethanol yield obtained was 56.3% using an N2 flow rate of 30 mL min−1, a yeast inoculation volume of 20 mL, and a moisture content of 4.6 mL (water) per g (substrate). The low residuals of ethanol and glucose in the substrate demonstrate that the N2 carrier gas effectively stripped the produced ethanol out of the packed bed, alleviating the inhibitions caused by evolved glucose and ethanol remaining in the bioreactor. With an increase in N2 flow rate or substrate moisture content, the total output of ethanol and ethanol yield initially increased and then decreased. However, with the increase in yeast inoculation volume, both indexes first rose and then remained relatively constant.